EPID-02. SURVIVAL BENEFIT OF GLIOBLASTOMA PATIENTS AFTER FDA APPROVAL OF BEVACIZUMAB, A POPULATION-BASED STUDY USING SEER, TCR, AND NCDB DATABASES

The nationwide studies on survival change in GBM patients treated with bevacizumab (BEV) after Food and Drug Administration (FDA) approval in May 2009 were limited. We investigated the impacts of BEV on survival in general GBM patient population by conducting a retrospective study based on the Surve...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Zhu, Ping, Du, Xianglin, Lu, Guangrong, Zhu, Jay-Jiguang
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2017
Konular:
Abstracts
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693197/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.280
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller